Kedrion confirms closing with FSI SGR

Released: 15/11/2019 – 13:44 GMT
RNS Number: 6238T
Kedrion S.p.A.


Milan, 15th November 2019 – Following the press release dated 16th October 2019, Kedrion S.p.A. confirms the closing on today’s date of the transaction involving the acquisition by FSI SGR S.p.A. of Company shares from Sestant Internazionale S.p.A. at the value of Euro 100 million together with the capital increase of Euro 50 million and the capital increase of Euro 16.7 million  by FSI Investimenti.


About Kedrion

Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.

The Company operates through a fully integrated business model from the collection of plasma in its own centers in the United States and Hungary to fractionation and production in its manufacturing facilities located in Italy, Hungary and the United States.

Headquartered in Castelvecchio Pascoli (Italy), Kedrion has over 2,500 employees and a commercial presence in approximately 100 countries worldwide.

Kedrion places a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves.

Additional information about Kedrion can be found at



This document contains forward-looking statements on overall economic development as well as on the business and assets position of Kedrion S.p.A. and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Kedrion does not intend to update the forward-looking statements and assumes no obligation to do so.